Effectiveness of ledipasvir/lofosbuvir plus ribavarin regimen in hepatitis C virus genotype 3 infection in patients with or without cirrhosis

Abstract

Background: In last few years direct-acting antiviral agents (DAAs) showed high efficacy in chronic hepatitis C treatment. One of them Ledipasvir/Sofosbuvir demonstrated almost 100% cure rate on specific genotypes. But the question of HCV 3 genotype patients’ treatment with Ledipasvir/Sofosbuvir is still under debate (due to the variable data). This study evaluates the efficacy of Ledipasvir/Sofosbuvir plus ribavirin regimen on HCV genotype 3 patients with/without cirrhosis. Has been conducted retrospective analysis of patients with HCV 3 genotype involved in the national hepatitis C elimination program of Georgia. The patients with or without cirrhosis were treated for 24 or 12 weeks respectively. Methods & Materials: The data of 1136 patients were analyzed who underwent treated in 2016-2017; in whom sustained virological response (SVR) was assessed 12 to 24 weeks after treatment. Most of them were non-cirrhotic 91.73% (1042) and 8.27% (94) had cirrhosis. Results: Overall SVR rate was 98.5% (1120 individuals); only 1.41% (16 patients) relapsed. SVR rate in non-cirrhotic patients was 98.8% (1030); in cirrhotic patients the same index was 95.7% (90). Conclusion: Ledipasvir/Sofosbuvir combination presented high cure rate in HCV genotype 3 patients, especially in non-cirrhotic patients; but the low rate of SVR in cirrhotic patients may be disputed due to the relatively low number of patients. Further research is recommended to make the relevant conclusion on the efficiency of ledipasvir/sofosbuvir in genotype 3 patients, especially in cirrhotic patients involving more number of patients.